Key takeaways
- Oak has introduced compounded semaglutide plans starting at $119 per month, which includes clinical review and shipping.
What happened
Telehealth provider Oak has launched a new compounded GLP-1 weight-loss program with pricing starting at $119 per month. According to the company's published promotional materials, this direct-to-consumer cash-pay option includes the medical provider review, the compounding medication, and free shipping under a single flat rate. The launch represents one of the lowest entry-level prices currently available in the online obesity care market.
Why it matters
This pricing shift is a major development for the millions of Americans who do not have insurance coverage for brand-name obesity medications. For patients paying out of pocket, brand-name GLP-1 medications like Wegovy and Zepbound routinely cost between $1,000 and $1,400 per month.
By introducing a plan at $119, Oak is significantly lowering the financial barrier to medical weight loss. Furthermore, because Oak does not charge an additional monthly membership fee, this pricing challenges the traditional telehealth subscription model where administrative fees are stacked on top of medication costs.
What the data says
Oak's promotional offer outlines several specific details regarding their new pricing structure and clinical process:
- The Entry Price: Compounded semaglutide plans start at $119 per month as part of a limited-time September offer that advertises a $200 discount.
- All-Inclusive Fees: The monthly starting price covers the clinical review, medical support, health coaching, and medication. There is no additional membership fee advertised.
- Shipping Policy: Free, tracked, two-day shipping from a U.S.-licensed pharmacy is included.
- The Clinical Process: The intake is 100% online, requiring an asynchronous health form with no video call or waiting room visit necessary. A licensed clinician reviews the submission within one day to determine eligibility.
- Treatment Options: The entry-level price is for compounded semaglutide (the active ingredient in Wegovy). Oak also offers compounded tirzepatide (the active ingredient in Zepbound, which acts as a dual GLP-1 and GIP agonist), with pricing and titration plans available upon provider inquiry.
How it compares
The $119 starting price significantly undercuts both brand-name cash prices and standard telehealth competitors. In its marketing materials, Oak contrasts its program against traditional cash-pay brand-name options, which range from $1,000 to $1,400 monthly, and other telehealth programs, which Oak notes typically range from $400 to $500 per month when combining medication and membership fees. Many of those alternative platforms charge separate membership fees of $50 to $99 per month and may require video consultations.
While Oak offers the same starting price at every dose, it is important to note that compounded medications are not FDA-approved finished products. Patients looking to understand how these alternatives differ from brand-name options can review our guide on compounded vs. brand-name semaglutide. For those evaluating different telehealth platforms and pricing tiers, our directory of providers and our roundup of the cheapest telehealth GLP-1 services offer detailed comparisons.
How this fits the bigger picture
Oak's aggressive pricing strategy arrives during a period of massive transition in the U.S. obesity care market. As consumer demand surges, the market is splitting into two distinct sectors: premium brand-name drugs and highly competitive, cash-pay compounded alternatives.
This shift is accelerating as policy proposals and market realities push buyers away from traditional insurance channels. For example, federal budget proposals, such as the suggested 70% cut to the CDC obesity division, signal a continuing shift toward private, cash-pay telehealth care. Similarly, while political proposals like proposed $500 health cash checks could eventually act as direct subsidies for these programs, low-cost options like Oak are already bringing the monthly cost of treatment well within reach for self-paying patients.
As telehealth platforms battle on price, they are also navigating complex safety and regulatory environments. The FDA recently issued safety alerts regarding administrative errors, as discussed in our report on the FDA warning against multidose vials for compounded GLP-1s. Telehealth platforms that bundle pre-filled single-dose syringes or offer clear clinical guidance are increasingly using safety and ease-of-use to differentiate themselves from bare-minimum compounding services.
What happens next
Oak's $119 promotional pricing is positioned as a limited-time September offer designed to help patients begin treatment ahead of the holidays. Moving forward, the industry will watch to see if competitors lower their own subscription fees to match this price point.
Additionally, the long-term availability of compounded semaglutide and tirzepatide remains tied to official FDA shortage declarations. If the FDA completely resolves the brand-name shortages, the regulatory allowances that permit compounding pharmacies to prepare copies of these drugs may change, forcing telehealth providers to pivot their clinical models.
CompareRx does not provide medical advice. Always consult a licensed healthcare provider to understand the risks, benefits, and appropriate treatment plans for weight management medications.